Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

NCT02515331 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Patients, Resistant Hypertension

Interventions

DRUG: LHW090
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals